Research Funding Awarded to Study Parkinson's Sleep
AstronauTx has secured new grants to investigate sleep mechanisms and protein clearance in Parkinson's disease.
Updated on Sept. 22, 2026 in Alzheimer’s
Live Poll
Do you believe sleep-based research offers a promising approach to treating complex neurological diseases?
The Michael J. Fox Foundation and Parkinson's UK have awarded research funding to London-based biotech firm AstronauTx. The company will partner with University College London to examine the link between restorative sleep and disease progression.
Why it matters
The research aims to determine if enhancing slow-wave sleep could influence the accumulation of pathological proteins. Scientists believe improving these restorative mechanisms may help address early indicators of Parkinson's disease, such as REM Sleep Behaviour Disorder.
AstronauTx previously secured £48 million/$61 million in Series A financing in October 2023. The new funding supports the evaluation of ligand-gated ion channel modulation for prodromal synucleinopathies.
The players
AstronauTx
This London-based biotechnology company focuses on the development of innovative therapeutics for Alzheimer's disease and other neurological conditions.
The Michael J. Fox Foundation
This foundation is a leading global non-profit organization dedicated to finding a cure for Parkinson's disease through funded research.
Parkinson's UK
This national charity provides support and funds scientific research to improve treatments for those living with Parkinson's disease.
University College London
This public research university is collaborating on the study to examine sleep mechanisms related to neurological health.
The details
The project funded by Parkinson's UK will use mouse models to test whether a sleep-enhancing compound can boost glymphatic flow and facilitate the clearance of alpha-synuclein. Simultaneously, the Michael J. Fox Foundation grant will support the investigation of novel compounds designed to reduce pathological protein accumulation.
Timeline
September 22, 2026: AstronauTx announced the receipt of new research funding.
2027: AstronauTx plans to begin clinical development of its lead programme.
The Big Picture
The project follows the established glymphatic system research model by testing whether pharmacological intervention can enhance waste clearance during sleep.
This research provides a potential new pathway for treating early-stage neurodegenerative markers like REM Sleep Behaviour Disorder. While still in early development, these findings could eventually change how physicians manage protein accumulation in high-risk patients.
The takeaway
This funding highlights a growing trend of targeting sleep health to slow the progression of neurological disorders. Readers should note that while this research is promising, clinical development for these compounds is not expected until at least 2027.
What happens next
AstronauTx is scheduled to move its lead development programme into clinical phases in 2027.
Further reading
Learn more about the latest breakthroughs in neurodegeneration by visiting our Alzheimer’s section.
Live Poll
Do you believe sleep-based research offers a promising approach to treating complex neurological diseases?
